Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 645
- Registration Number
- NCT02314117
- Locations
- 🇺🇸
UT Southwestern Med Ctr, Dallas, Texas, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02307812
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 80
- Registration Number
- NCT02213289
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT02082210
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02079636
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Indiana Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸The West Clinic, Germantown, Tennessee, United States
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT01983878
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 197
- Registration Number
- NCT01703091
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan
A Study of LY2801653 in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 190
- Registration Number
- NCT01285037
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT01246986
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.